(Q45176495)

10 December 2017

title

Levetiracetam for people with mental retardation and refractory epilepsy (English)

1 reference

10 December 2017

1 reference

2

Linda J Stephen

0 references

Martin J Brodie

3

object named as

Martin J Brodie

0 references

author name string

Kevin Kelly

1

1 reference

10 December 2017

Linda J Stephen

2

1 reference

10 December 2017

Martin J Brodie

3

1 reference

10 December 2017

publication date

1 December 2004

1 reference

10 December 2017

1 reference

10 December 2017

volume

5

1 reference

10 December 2017

issue

6

1 reference

10 December 2017

page(s)

878-883

1 reference

Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

ucb L059, a novel anti-convulsant drug: pharmacological profile in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Effect of levetiracetam in refractory childhood epilepsy syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Levetiracetam treatment of idiopathic generalised epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Epilepsy and learning disabilities--a challenge for the next millennium?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Pharmacological outcomes in people with mental retardation and epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Treatment of seizures in patients with learning disabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Clinical guidelines for the management of epilepsy in adults with an intellectual disability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Topiramate in patients with learning disability and refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Levetiracetam in refractory epilepsy: a prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Levetiracetam psychosis in children with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Psychiatric adverse events during levetiracetam therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Antiepileptic drugs as a cause of worsening seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.009

10.1016/J.YEBEH.2004.07.009

7 January 2021

Identifiers

DOI

1 reference

10 December 2017

1 reference